Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have earned an average rating of “Buy” from the twelve research firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $55.50.
Several research firms have weighed in on HRTX. BidaskClub upgraded Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, April 3rd. Northland Securities set a $55.00 target price on Heron Therapeutics and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald downgraded Heron Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, March 4th. ValuEngine cut Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Finally, Stifel Nicolaus restated a “buy” rating and set a $54.00 price objective on shares of Heron Therapeutics in a report on Friday, February 22nd.
HRTX stock traded down $0.48 during midday trading on Monday, hitting $24.44. 9,154 shares of the company’s stock were exchanged, compared to its average volume of 887,968. The firm has a market cap of $1.95 billion, a PE ratio of -10.00 and a beta of 1.55. Heron Therapeutics has a one year low of $21.25 and a one year high of $42.90.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Friday, February 22nd. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.17). The business had revenue of $28.84 million for the quarter, compared to the consensus estimate of $28.05 million. Heron Therapeutics had a negative return on equity of 54.98% and a negative net margin of 230.84%. On average, sell-side analysts expect that Heron Therapeutics will post -1.52 earnings per share for the current year.
Hedge funds have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV acquired a new stake in Heron Therapeutics in the first quarter valued at $896,000. Chartwell Investment Partners LLC boosted its position in Heron Therapeutics by 98.6% during the first quarter. Chartwell Investment Partners LLC now owns 99,042 shares of the biotechnology company’s stock valued at $2,421,000 after acquiring an additional 49,160 shares during the last quarter. Mesirow Financial Investment Management Inc. boosted its position in Heron Therapeutics by 47.0% during the first quarter. Mesirow Financial Investment Management Inc. now owns 19,553 shares of the biotechnology company’s stock valued at $478,000 after acquiring an additional 6,254 shares during the last quarter. American Century Companies Inc. boosted its position in Heron Therapeutics by 1.7% during the fourth quarter. American Century Companies Inc. now owns 134,526 shares of the biotechnology company’s stock valued at $3,490,000 after acquiring an additional 2,278 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Heron Therapeutics by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 751,250 shares of the biotechnology company’s stock valued at $19,487,000 after acquiring an additional 26,429 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also: What is insider trading?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.